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We read with interest the review on advanced carotid
imaging techniques. Hermus and colleagues highlight the
predominant role of FDG-PET in imaging plaque inflamma-
tion in humans. We wish to point out however that FDG-PET
is limited by its spatial resolution (order of 4e5 mm). The
advent of integrated CT-PET technology should provide
automatic co-registration of areas of high signal on PET with
the structural information provided by CT. Another disad-
vantage of PET-FDG imaging is the associated radiation
burden, which limits the number of PET studies that patients
can have (2 in total), reducing its potential contribution in
assessing therapeutic interventions. It is also not formally
licensed to be used in diabetics by the Food & Drug Admin-
istration in the US, excluding an important group of vascu-
lopaths for imaging and potential risk stratification.
The authors briefly discuss the role of nanoparticles in
carotid plaque inflammation imaging and state that high
resolution MRI using nanoparticles has only been used in
animal studies (Table 3). This is not accurate. It has been
possible to image carotid plaque inflammation with Ultra
small Super-Paramagnetic Iron Oxide (USPIO) enhanced MRI
in humans.1 The use of a USPIO contrast medium e
Sinerem (Guerbet, Roissy, France), has allowed the direct
visualization of macrophage infiltration of carotid atheroma
in-vivo. Furthermore, Sinerem has been used as the first
targeted MR contrast medium to assess therapeutic
response in an interventional anti-inflammatory drug trial
in patients with carotid disease.2 Simultaneously it facili-
tated the enrichment of a trial population so that only
individuals with plaque inflammation were selected for
enrolment into the study.
We would be interested to hear the authors’ thoughts on
which technique holds the most promise as a biomarker in
inflammatory atheroma imaging.
References
1 Trivedi RA, Mallawarachi C, UK-I JM, Graves MJ, Horsley J,
Goddard MJ, Brown A, Wang L, Kirkpatrick PJ, Brown J,
Gillard JH. Identifying inflamed carotid plaques using in vivo
USPIO-enhanced MR imaging to label plaque macrophages. Arter
Throm Vasc Biol 2006;26:1601e6.DOI of original article: 10.1016/j.ejvs.2009.11.020.2 Tang TY, Howarth SP, Miller SR, Graves MJ, Patterson AJ, UK-I JM,
Li ZY, Walsh SR, Brown AP, Kirkpatrick PJ, Warburton EA,
Hayes PD, Varty K, Boyle JR, Gaunt ME, Zalewski A, Gillard JH.
The ATHEROMA (Atorvastatin therapy: effects on reduction of
macrophage activity) study. Evaluation using ultrasmall super-
paramagnetic iron oxide-enhanced magnetic resonance imaging
in carotid disease. J Am Coll Cardio 2009;53:2039e50.
T.Y. Tang*
Vascular Unit, Norfolk & Norwich, University Hospital,
Norfolk, UK
University Department of Radiology, Cambridge University
Hospitals NHS Foundation Trust, Cambridge, UK
*Corresponding author: Box 218, Addenbrooke’s Hospital,
Hills Road, Cambridge CB2 0QQ, UK. Tel þ44 1223 767926;
fax þ44 1223 330915.
E-mail address: tt279@cam.ac.uk
S.R. Walsh
Cambridge Vascular Unit, Cambridge University Hospitals
NHS Foundation Trust, Cambridge, UK
U. Sadat
Cambridge Vascular Unit, Cambridge University Hospitals
NHS Foundation Trust, Cambridge, UK
University Department of Radiology, Cambridge University
Hospitals NHS Foundation Trust, Cambridge, UK
J.H. Gillard
University Department of Radiology, Cambridge University
Hospitals NHS Foundation Trust, Cambridge, UK
Available online 24 April 2010
ª 2010 European Society for Vascular Surgery. Published by Elsevier
Ltd. All rights reserved.
doi:10.1016/j.ejvs.2010.03.033
Response to Comment on “Advanced Carotid
Plaque Imaging”Dear Editor,
We would like to thank Tang and colleagues for their remarks
to our previous article and for the opportunity to highlightDOI of original article: 10.1016/j.ejvs.2010.03.033.
140 Correspondencethe issues regarding new advanced imaging techniques in
carotid plaque imaging. We agree with Tang et al. that the
statement of HR-MRI with magnetic nanoparticles being
performed in animal studies only is indeed incorrect. USPIO
HR-MRI imaging has shown to correspond with macrophage
accumulation and thereby identifies inflammatory plaques in
patients with carotid artery disease. The combination of
detailed anatomic and functional information as obtained by
HR-MRI using nanoparticles may therefore be of additional
value in the selection of high-risk plaques.
18F-FDG-PET scanning, especially when combined with
anatomical imaging modalities such as CT or HR-MRI, has also
repeatedly shown to identify inflammatory activity in
atherosclerotic plaques.1 In addition, serial prospective
18F-FDG-PET studies have reported an excellent interob-
server, intraobserver and interscan reproducibility.2 In dia-
betic patients, FDG-PET imaging requires strict glucose
regulation to obtain reliable images.3 However, FDG-PET
imaging has been widely used in oncological settings in dia-
betic and non-diabetic patients.
When compared to USPIO HR-MRI imaging, FDG-PET obvi-
ously has the disadvantage of radiation burden. However, FDG
dose reduction can be achieved by using new techniques such
as time of flight technology. In addition, CT-scan radiation
dose can be reduced by xeyez axis dose modulation.
A practical advantage of FDG-PET is patient conve-
nience; FDG-PET scanning can be done in a one day setting
(60e90 min after injection of 18F-FDG) whereas USPIO
images are obtained after 24e36 h.
Both modalities provide information on macrophage
infiltration and plaque inflammation and at this stage neither
of them is ready for regular use in clinical practice. Optimal
standards of quantification of USPIO and FDG uptake and
imaging protocols have to be determined and prospectivestudies linking FDG or USPIO inflammatory activity to future
cardiovascular events should be performed.
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